Focal neuroinflammation is considered one of the hypotheses for the cause of temporal lobe epilepsy (TLE) with amygdala enlargement (AE). Here, we report a case involving an adult female patient with TLE-AE characterized by late-onset seizures and cognitive impairment. Anti-N-methyl-D-aspartate receptor (NMDAR) antibodies were detected in her cerebrospinal fluid. However, administration of appropriate anti-seizure drugs (ASD), without immunotherapy, improved TLE-AE associated with NMDAR antibodies. In the present case, two clinically significant observations were made: 1) anti-NMDAR antibody-mediated autoimmune processes may be associated with TLE-AE, and 2) appropriate administration of ASD alone can improve clinical symptoms in mild cases of autoimmune epilepsy.
Introduction
In recent years, an increasing number of reports have indicated an association between
ACCEPTED MANUSCRIPT

A C C E P T E D M A N U S C R I P T
amygdala enlargement (AE) and temporal lobe epilepsy (TLE) [1] . Focal neuroinflammation is considered one of the hypotheses for the cause of TLE-AE.
However, the etiology is not fully understood, and there is no consensus regarding its treatment. Here, we describe a patient with TLE-AE associated with anti-N-methyl-D-aspartate receptor (NMDAR) antibody. Administration of appropriate anti-seizure drugs (ASD), without immunotherapy, improved her clinical symptoms.
Case
A right-handed female office worker in her 50's was admitted to Hospital A for the evaluation of cognitive dysfunctions, emotional disturbances, and suspected epilepsy.
She had a history of breast cancer (stage 0) in her 40's, but no other significant medical history. She had experienced impaired attention, memory deficits, and emotional instability for 6 years. She received various pharmacotherapies under the diagnosis of depression or early-onset dementia, but her symptoms did not improve. At Year X-2, her colleagues witnessed her staring at a point, having stopped her work, suggesting the possibility of epileptic seizures; therefore, she began receiving valproic acid, 400 mg daily. However, brief episodes of impaired consciousness continued, and her cognitive dysfunction gradually worsened. Consequently, she was forced to discontinue working.
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On mental status examination, she demonstrated bradykinesia and bradyphrenia. Her family reported witnessing focal seizures, with loss of consciousness, on a weekly to monthly basis.
We recorded one habitual seizure during a 24-hour inpatient video electroencephalographic (EEG) monitoring. A focal impaired awareness seizure, with behavioral arrest, blank stare, and unresponsiveness, lasted approximately 50 seconds.
Ictal EEG recordings showed rhythmic waves of varying amplitude and frequency in the The diagnosis of TLE-AE was established, and she was started on carbamazepine (CBZ), 200 mg daily. After starting CBZ, focal impaired awareness seizures were controlled; her mood symptoms and cognitive impairment also abated. She was discharged home on CBZ medication, following which, her treatment was changed to zonisamide (ZNS) monotherapy because of a rash.
Cerebrospinal fluid (CSF) antibody test results arrived during outpatient follow-up, and
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revealed the presence of anti-NMDAR antibodies, detected by both cell-based assay and enzyme-linked immunosorbent assay. We performed a search for underlying tumors, but none were found.
Immunotherapy was proposed because we suspected that anti-NMDAR antibody-mediated autoimmune processes might cause TLE-AE, but the patient and her family were reluctant to implement it because they believed she had already recovered to her premorbid state. We respected their opinions and decided to treat her without administering immunotherapy. During a 3-year follow-up, she maintained seizure freedom on ZNS medication (200 mg daily), and neuropsychological examination revealed that her verbal intelligence quotient and memory functions were particularly improved ( Fig. 2 ). Moreover, reduction in the volume of the enlarged amygdala was observed on MRI. The most recent MRI showed that the difference in volume between the left and right amygdalae had disappeared. Subsequently, she regained her job and continues to work. She provided written informed consent for the publication of this case report.
Discussion
In the present case, we made two clinically significant observations: 1) anti-NMDAR
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T
antibody-mediated autoimmune processes may be associated with TLE-AE, 2) appropriate administration of ASD alone can improve clinical symptoms in mild cases with autoimmune TLE-AE.
First, Anti-NMDAR antibody-mediated autoimmune processes may be associated with TLE-AE. In our patient, the characteristics of the seizure-related features were: a later onset of seizure; greater frequency of focal impaired awareness, rather than convulsive, seizures; and ipsilateral interictal discharges to the enlarged amygdala. Her MRI findings are consistent with those in previous reports of TLE-AE [1] . Besides the common features of TLE-AE, other clinical features, such as memory and emotional disturbances, and presence of anti-NMDAR antibodies in CSF, also meet the proposed diagnostic criteria for anti-NMDAR encephalitis [2] . However, the present case was different from the typical anti-NMDAR encephalitis in that the progress was slow and there were no other symptoms, such as abnormal movements, decreased level of consciousness, or autonomic dysfunction. Therefore, we believe that our patient presented with a milder form or "forme fruste" of anti-NMDAR encephalitis. To date, a However, immunological tests have not been performed in many such cases, and the existence of antibodies may have been overlooked.
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It is generally believed that immediate immunotherapy should be considered to prevent severe consequences when autoimmune etiology is suspected. However, in our patient, administration of ASD, without immunotherapy, terminated her TLE-AE seizures. As a result, her cognitive functions improved and she was able to achieve social participation.
Similar to our case, some studies have reported cases involving patients with autoimmune epilepsy who respond adequately to treatment with ASD alone [5] [6] [7] .
The largest observational study of 50 patients revealed that 10% of the patients with autoimmune epilepsy had become seizure-free with ASD treatment alone, and all of them had received ASD with sodium channel blocking properties, such as CBZ, phenytoin, lacosamide, and oxcarbazepine [7] . In a systematic review, Cabezudo-García et al. found that many of these patients were treated with ASD having sodium channel blocking properties [8] . The reason why only such ASD achieved seizure control in autoimmune epilepsy is unknown, but it is hypothesized that sodium channel blockers improve autoimmune encephalitis indirectly through their strong anti-seizure action for focal seizures or directly affect immune systems [5] [7].
Remission of AE was observed in our patient on MRI, which is consistent with a predictor for a favorable clinical outcome described in a previous study [4] . Therefore,
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it is important to observe the change in the volume of the enlarged amygdala by MRI during regular follow-ups. Voh Rhein et al. suggested that physicians should start treatment with ASD in mild cases of autoimmune encephalitis, evaluate its effectiveness, and initiate immunotherapy if there is an exacerbation of seizures, a deterioration of cognition or mood, or progress of the disease is indicated by MRI findings during follow-ups across 3 months [9] . By using these treatment strategies, it is possible to avoid unnecessary consumption of medical resources and the unacceptable side effects of immunotherapy. Moreover, these strategies may help avert the side effects from immunotherapy and extend to patients with contradictions to immunotherapy.
In conclusion, anti-NMDAR antibody-mediated autoimmune processes may be associated with TLE-AE, and appropriate administration of ASD alone can improve clinical symptoms in patients with a milder form of autoimmune TLE-AE. Further reports should be accumulated to determine whether anti-NMDAR-associated autoimmune pathology is present more frequently in TLE-AE, and whether the prognosis of a patient group treated with only ASD differs from that of a group receiving combination treatment with ASD and immunotherapy, in mild and subacute/chronic cases. 
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Figure legends
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Neuropsychological examinations reveal the changes in the patient's verbal IQ and memory as the left temporal function was particularly improved after the cessation of seizures due to appropriate ASD.
WAIS-III: Wechsler Adult Intelligence Scale -Third Edition, WMS-R: Wechsler
Memory Scale -Revised, IQ: Intelligence Quotient
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Highlights -Anti-N-methyl-D-aspartate receptor (NMDAR) antibody-mediated autoimmune processes may be associated with temporal lobe epilepsy with amygdala enlargement.
-Administration of appropriate antiepileptic drug, without immunotherapy, improved both epileptic seizures and cognitive function in this patient.
-This patient presented with a milder form or "forme fruste" of anti-NMDAR encephalitis. 
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